JP2012506860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506860A5 JP2012506860A5 JP2011533326A JP2011533326A JP2012506860A5 JP 2012506860 A5 JP2012506860 A5 JP 2012506860A5 JP 2011533326 A JP2011533326 A JP 2011533326A JP 2011533326 A JP2011533326 A JP 2011533326A JP 2012506860 A5 JP2012506860 A5 JP 2012506860A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tiotropium
- composition according
- formoterol
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 32
- 229940110309 tiotropium Drugs 0.000 claims description 30
- 229960002848 formoterol Drugs 0.000 claims description 14
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 13
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 229960001692 arformoterol Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000007883 bronchodilation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 239000007788 liquid Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 208000000884 Airway Obstruction Diseases 0.000 claims 5
- 230000002441 reversible effect Effects 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010062109 Reversible airways obstruction Diseases 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- -1 formoterol formoterol stereoisomers Chemical class 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 31
- 230000006872 improvement Effects 0.000 description 20
- 238000011284 combination treatment Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 206010013975 Dyspnoeas Diseases 0.000 description 8
- 230000004199 lung function Effects 0.000 description 8
- 208000000059 Dyspnea Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009097 single-agent therapy Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940124630 bronchodilator Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010059487 Lung hyperinflation Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 230000008371 airway function Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10796408P | 2008-10-23 | 2008-10-23 | |
| US61/107,964 | 2008-10-23 | ||
| PCT/US2009/061652 WO2010048384A2 (en) | 2008-10-23 | 2009-10-22 | Arformoterol and tiotropium compositions and methods for use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014143813A Division JP2014237666A (ja) | 2008-10-23 | 2014-07-14 | アルホルモテロール及びチオトロピウムの組成物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012506860A JP2012506860A (ja) | 2012-03-22 |
| JP2012506860A5 true JP2012506860A5 (enExample) | 2012-12-20 |
Family
ID=42119978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533326A Pending JP2012506860A (ja) | 2008-10-23 | 2009-10-22 | アルホルモテロール及びチオトロピウムの組成物及びその使用方法 |
| JP2014143813A Pending JP2014237666A (ja) | 2008-10-23 | 2014-07-14 | アルホルモテロール及びチオトロピウムの組成物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014143813A Pending JP2014237666A (ja) | 2008-10-23 | 2014-07-14 | アルホルモテロール及びチオトロピウムの組成物及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20110250242A1 (enExample) |
| EP (1) | EP2355808A4 (enExample) |
| JP (2) | JP2012506860A (enExample) |
| AU (1) | AU2009308412B2 (enExample) |
| CA (1) | CA2741078A1 (enExample) |
| TW (1) | TW201021792A (enExample) |
| WO (1) | WO2010048384A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019142214A1 (en) * | 2018-01-19 | 2019-07-25 | Cipla Limited | Pharmaceutical composition comprising tiotropium for inhalation |
| CN111481550A (zh) * | 2020-05-14 | 2020-08-04 | 王兆霖 | 含有噻托溴铵和阿福特罗的药物制剂 |
| CN115267024B (zh) * | 2022-07-31 | 2023-06-30 | 浙江知一药业有限责任公司 | 治疗呼吸系统疾病的药物组合物及其检测方法 |
| CN117679423A (zh) | 2022-09-05 | 2024-03-12 | 立生医药(苏州)有限公司 | 预防或治疗呼吸系统疾病的吸入用药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL122752A (en) * | 1995-06-27 | 2001-07-24 | Boehringer Ingelheim Kg | Stable preparations for creating propellant-free sprays |
| US20040019025A1 (en) * | 2000-04-18 | 2004-01-29 | Gavin Brian Charles | Medical compositions comprising (r,r)-formoterol and rofleponide |
| AU5070100A (en) * | 2000-05-22 | 2001-12-03 | Chiesi Farma Spa | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| SI3494995T1 (sl) * | 2002-03-01 | 2020-08-31 | Chiesi Farmaceutici S.P.A. | Superfina formulacija formoterola |
| US20060079544A1 (en) * | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| EA200700600A1 (ru) * | 2004-09-09 | 2008-02-28 | Сипла Лимитед | Фармацевтическая композиция, содержащая изомер бета-миметического агента и антихолинергический агент |
| US20070293460A1 (en) * | 2005-10-31 | 2007-12-20 | Richie's Pharmacy And Medical Supply, Incorporated | Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease |
| EP2124915A2 (en) * | 2007-02-19 | 2009-12-02 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
-
2009
- 2009-10-22 CA CA2741078A patent/CA2741078A1/en not_active Abandoned
- 2009-10-22 JP JP2011533326A patent/JP2012506860A/ja active Pending
- 2009-10-22 AU AU2009308412A patent/AU2009308412B2/en not_active Ceased
- 2009-10-22 EP EP09822693A patent/EP2355808A4/en not_active Withdrawn
- 2009-10-22 US US13/125,506 patent/US20110250242A1/en not_active Abandoned
- 2009-10-22 WO PCT/US2009/061652 patent/WO2010048384A2/en not_active Ceased
- 2009-10-23 TW TW098135905A patent/TW201021792A/zh unknown
-
2014
- 2014-07-14 JP JP2014143813A patent/JP2014237666A/ja active Pending
- 2014-07-25 US US14/340,736 patent/US20140336218A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003260754B2 (en) | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids | |
| EP2600830B1 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| EP1718336B1 (en) | Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases | |
| JP2013056947A (ja) | 気管支感染症の治療法 | |
| US20090192187A1 (en) | Dry powder formulation comprising an anticholinergic drug | |
| TWI905086B (zh) | 包含雷芬那新（ｒｅｖｅｆｅｎａｃｉｎ）之醫藥組合物用於治療慢性阻塞性肺疾病之用途及選擇治療用之吸入遞送裝置之方法 | |
| KR101621676B1 (ko) | 천식의 병세악화를 예방 및/또는 치료하기 위한 포르모테롤 및 베클로메타손 디프로피오네이트를 포함하는 조성의 용도 | |
| US20160106664A1 (en) | Novel propellant containing preparations for tiotropium | |
| US20040009963A1 (en) | Use of salmeterol and fluticasone propionate combination | |
| JP2012506860A5 (enExample) | ||
| TW201735914A (zh) | 用於治療慢性阻塞性肺疾病之醫藥組成物 | |
| JP2014237666A (ja) | アルホルモテロール及びチオトロピウムの組成物及びその使用方法 | |
| WO2023212191A9 (en) | Combination of albuterol and budesonide for the treatment of asthma | |
| Micheletto et al. | Triple therapy in COPD | |
| Janson et al. | 4. ACUTE ASTHMA AND COPD EXACERBATIONS | |
| WO2021211854A1 (en) | Inhalable formulation of a solution containing tiotropium bromide |